(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 29,806\u00a0 | $ | 32,400\u00a0 | |||||||
Restricted cash - current | 5,405\u00a0 | 3,333\u00a0 | |||||||||
Total current assets | 35,211\u00a0 | 35,733\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 1,045\u00a0 | 1,333\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 36,256\u00a0 | $ | 37,066\u00a0 |
(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 29,806\u00a0 | $ | 32,400\u00a0 | |||||||
Restricted cash - current | 5,405\u00a0 | 3,333\u00a0 | |||||||||
Total current assets | 35,211\u00a0 | 35,733\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 1,045\u00a0 | 1,333\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 36,256\u00a0 | $ | 37,066\u00a0 |
(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 29,806\u00a0 | $ | 32,400\u00a0 | |||||||
Restricted cash - current | 5,405\u00a0 | 3,333\u00a0 | |||||||||
Total current assets | 35,211\u00a0 | 35,733\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 1,045\u00a0 | 1,333\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 36,256\u00a0 | $ | 37,066\u00a0 |
(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
| Computer hardware | $ | 19,100\u00a0 | $ | 17,680\u00a0 | |||||||
Machinery and equipment(1) | 20,162\u00a0 | 18,239\u00a0 | |||||||||
| Leasehold improvements | 17,413\u00a0 | 17,390\u00a0 | |||||||||
| Furniture and fixtures | 4,671\u00a0 | 4,671\u00a0 | |||||||||
| Work in progress | 152\u00a0 | 229\u00a0 | |||||||||
| Total | 61,498\u00a0 | 58,209\u00a0 | |||||||||
Less accumulated depreciation(2) | (48,251) | (43,632) | |||||||||
| Property and equipment\u2014net | $ | 13,247\u00a0 | $ | 14,577\u00a0 |
(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
| Computer hardware | $ | 19,100\u00a0 | $ | 17,680\u00a0 | |||||||
Machinery and equipment(1) | 20,162\u00a0 | 18,239\u00a0 | |||||||||
| Leasehold improvements | 17,413\u00a0 | 17,390\u00a0 | |||||||||
| Furniture and fixtures | 4,671\u00a0 | 4,671\u00a0 | |||||||||
| Work in progress | 152\u00a0 | 229\u00a0 | |||||||||
| Total | 61,498\u00a0 | 58,209\u00a0 | |||||||||
Less accumulated depreciation(2) | (48,251) | (43,632) | |||||||||
| Property and equipment\u2014net | $ | 13,247\u00a0 | $ | 14,577\u00a0 |
(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
| Software | $ | 30,727\u00a0 | $ | 28,306\u00a0 | |||||||
| Work in progress | 444\u00a0 | 18\u00a0 | |||||||||
| Total | 31,171\u00a0 | 28,324\u00a0 | |||||||||
Less accumulated amortization(1) | (14,218) | (13,264) | |||||||||
| Software\u2014net | $ | 16,953\u00a0 | $ | 15,060\u00a0 |
(in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
| Software | $ | 30,727\u00a0 | $ | 28,306\u00a0 | |||||||
| Work in progress | 444\u00a0 | 18\u00a0 | |||||||||
| Total | 31,171\u00a0 | 28,324\u00a0 | |||||||||
Less accumulated amortization(1) | (14,218) | (13,264) | |||||||||
| Software\u2014net | $ | 16,953\u00a0 | $ | 15,060\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Finance lease costs(1) | $ | 217\u00a0 | $ | 148\u00a0 | $ | 663\u00a0 | $ | 397\u00a0 | |||||||||||||||
Operating lease costs(2) | 1,885\u00a0 | 1,845\u00a0 | 5,704\u00a0 | 5,362\u00a0 | |||||||||||||||||||
| Short-term lease costs | 66\u00a0 | 63\u00a0 | 199\u00a0 | 188\u00a0 | |||||||||||||||||||
Variable lease costs(3) | 189\u00a0 | 199\u00a0 | 614\u00a0 | 481\u00a0 | |||||||||||||||||||
| Sublease income | (529) | (559) | (1,487) | (1,673) | |||||||||||||||||||
| Total net lease costs | $ | 1,828\u00a0 | $ | 1,696\u00a0 | $ | 5,693\u00a0 | $ | 4,755\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2026 | $ | 1,962\u00a0 | $ | 200\u00a0 | $ | 2,162\u00a0 | ||||||||||||||
| 2027 | 7,267\u00a0 | 773\u00a0 | 8,040\u00a0 | |||||||||||||||||
| 2028 | 6,906\u00a0 | 697\u00a0 | 7,603\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| Thereafter | 12,985\u00a0 | \u2014\u00a0 | 12,985\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 40,741\u00a0 | 2,117\u00a0 | 42,858\u00a0 | |||||||||||||||||
| Less: interest | 13,398\u00a0 | 411\u00a0 | 13,809\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 27,343\u00a0 | $ | 1,706\u00a0 | $ | 29,049\u00a0 |
| (in thousands) | Total | |||||||
| Remainder fiscal 2026 | $ | 603\u00a0 | ||||||
| 2027 | 2,102\u00a0 | |||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| 2030 | 161\u00a0 | |||||||
| Total sublease income | $ | 6,728\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Finance lease costs(1) | $ | 217\u00a0 | $ | 148\u00a0 | $ | 663\u00a0 | $ | 397\u00a0 | |||||||||||||||
Operating lease costs(2) | 1,885\u00a0 | 1,845\u00a0 | 5,704\u00a0 | 5,362\u00a0 | |||||||||||||||||||
| Short-term lease costs | 66\u00a0 | 63\u00a0 | 199\u00a0 | 188\u00a0 | |||||||||||||||||||
Variable lease costs(3) | 189\u00a0 | 199\u00a0 | 614\u00a0 | 481\u00a0 | |||||||||||||||||||
| Sublease income | (529) | (559) | (1,487) | (1,673) | |||||||||||||||||||
| Total net lease costs | $ | 1,828\u00a0 | $ | 1,696\u00a0 | $ | 5,693\u00a0 | $ | 4,755\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2026 | $ | 1,962\u00a0 | $ | 200\u00a0 | $ | 2,162\u00a0 | ||||||||||||||
| 2027 | 7,267\u00a0 | 773\u00a0 | 8,040\u00a0 | |||||||||||||||||
| 2028 | 6,906\u00a0 | 697\u00a0 | 7,603\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| Thereafter | 12,985\u00a0 | \u2014\u00a0 | 12,985\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 40,741\u00a0 | 2,117\u00a0 | 42,858\u00a0 | |||||||||||||||||
| Less: interest | 13,398\u00a0 | 411\u00a0 | 13,809\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 27,343\u00a0 | $ | 1,706\u00a0 | $ | 29,049\u00a0 |
| (in thousands) | Total | |||||||
| Remainder fiscal 2026 | $ | 603\u00a0 | ||||||
| 2027 | 2,102\u00a0 | |||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| 2030 | 161\u00a0 | |||||||
| Total sublease income | $ | 6,728\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Finance lease costs(1) | $ | 217\u00a0 | $ | 148\u00a0 | $ | 663\u00a0 | $ | 397\u00a0 | |||||||||||||||
Operating lease costs(2) | 1,885\u00a0 | 1,845\u00a0 | 5,704\u00a0 | 5,362\u00a0 | |||||||||||||||||||
| Short-term lease costs | 66\u00a0 | 63\u00a0 | 199\u00a0 | 188\u00a0 | |||||||||||||||||||
Variable lease costs(3) | 189\u00a0 | 199\u00a0 | 614\u00a0 | 481\u00a0 | |||||||||||||||||||
| Sublease income | (529) | (559) | (1,487) | (1,673) | |||||||||||||||||||
| Total net lease costs | $ | 1,828\u00a0 | $ | 1,696\u00a0 | $ | 5,693\u00a0 | $ | 4,755\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2026 | $ | 1,962\u00a0 | $ | 200\u00a0 | $ | 2,162\u00a0 | ||||||||||||||
| 2027 | 7,267\u00a0 | 773\u00a0 | 8,040\u00a0 | |||||||||||||||||
| 2028 | 6,906\u00a0 | 697\u00a0 | 7,603\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| Thereafter | 12,985\u00a0 | \u2014\u00a0 | 12,985\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 40,741\u00a0 | 2,117\u00a0 | 42,858\u00a0 | |||||||||||||||||
| Less: interest | 13,398\u00a0 | 411\u00a0 | 13,809\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 27,343\u00a0 | $ | 1,706\u00a0 | $ | 29,049\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2026 | $ | 1,962\u00a0 | $ | 200\u00a0 | $ | 2,162\u00a0 | ||||||||||||||
| 2027 | 7,267\u00a0 | 773\u00a0 | 8,040\u00a0 | |||||||||||||||||
| 2028 | 6,906\u00a0 | 697\u00a0 | 7,603\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| Thereafter | 12,985\u00a0 | \u2014\u00a0 | 12,985\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 40,741\u00a0 | 2,117\u00a0 | 42,858\u00a0 | |||||||||||||||||
| Less: interest | 13,398\u00a0 | 411\u00a0 | 13,809\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 27,343\u00a0 | $ | 1,706\u00a0 | $ | 29,049\u00a0 |
| (in thousands) | Total | |||||||
| Remainder fiscal 2026 | $ | 603\u00a0 | ||||||
| 2027 | 2,102\u00a0 | |||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| 2030 | 161\u00a0 | |||||||
| Total sublease income | $ | 6,728\u00a0 |
| March 31, 2026 | June 30, 2025 | ||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Impairment Charges | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||||||||||||||||||
| Customer relationships | $ | 1,423\u00a0 | $ | (1,404) | $ | 19\u00a0 | $ | 17,492\u00a0 | $ | (4,209) | $ | (13,252) | $ | 31\u00a0 | |||||||||||||||||||||||||||
| Trade name | \u2014\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 2,680\u00a0 | \u2014\u00a0 | (2,680) | \u2014\u00a0 | ||||||||||||||||||||||||||||||||||
| Proprietary software | 4,342\u00a0 | (3,243) | 1,099\u00a0 | 4,342\u00a0 | \u2014\u00a0 | (2,418) | 1,924\u00a0 | ||||||||||||||||||||||||||||||||||
| Non-compete agreements | 100\u00a0 | (98) | 2\u00a0 | 100\u00a0 | \u2014\u00a0 | (82) | 18\u00a0 | ||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 5,865\u00a0 | $ | (4,745) | $ | 1,120\u00a0 | $ | 24,614\u00a0 | $ | (4,209) | $ | (18,432) | $ | 1,973\u00a0 |
| Proprietary Software | Non-compete agreements | Customer relationships | Total | ||||||||||||||||||||
| Remainder of 2026 | $ | 275\u00a0 | $ | 2\u00a0 | $ | 5\u00a0 | $ | 282\u00a0 | |||||||||||||||
| 2027 | 824\u00a0 | \u2014\u00a0 | 14\u00a0 | 838\u00a0 | |||||||||||||||||||
| Total | $ | 1,099\u00a0 | $ | 2\u00a0 | $ | 19\u00a0 | $ | 1,120\u00a0 |
| March 31, 2026 | June 30, 2025 | ||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Impairment Charges | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||||||||||||||||||
| Customer relationships | $ | 1,423\u00a0 | $ | (1,404) | $ | 19\u00a0 | $ | 17,492\u00a0 | $ | (4,209) | $ | (13,252) | $ | 31\u00a0 | |||||||||||||||||||||||||||
| Trade name | \u2014\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 2,680\u00a0 | \u2014\u00a0 | (2,680) | \u2014\u00a0 | ||||||||||||||||||||||||||||||||||
| Proprietary software | 4,342\u00a0 | (3,243) | 1,099\u00a0 | 4,342\u00a0 | \u2014\u00a0 | (2,418) | 1,924\u00a0 | ||||||||||||||||||||||||||||||||||
| Non-compete agreements | 100\u00a0 | (98) | 2\u00a0 | 100\u00a0 | \u2014\u00a0 | (82) | 18\u00a0 | ||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 5,865\u00a0 | $ | (4,745) | $ | 1,120\u00a0 | $ | 24,614\u00a0 | $ | (4,209) | $ | (18,432) | $ | 1,973\u00a0 |
| Proprietary Software | Non-compete agreements | Customer relationships | Total | ||||||||||||||||||||
| Remainder of 2026 | $ | 275\u00a0 | $ | 2\u00a0 | $ | 5\u00a0 | $ | 282\u00a0 | |||||||||||||||
| 2027 | 824\u00a0 | \u2014\u00a0 | 14\u00a0 | 838\u00a0 | |||||||||||||||||||
| Total | $ | 1,099\u00a0 | $ | 2\u00a0 | $ | 19\u00a0 | $ | 1,120\u00a0 |
| (in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
Term Loan | $ | 325,000\u00a0 | $ | \u2014\u00a0 | |||||||
Previous Term Loans | \u2014\u00a0 | 314,000\u00a0 | |||||||||
Class A Notes | 41,044\u00a0 | 50,054\u00a0 | |||||||||
Class B Notes | 27,363\u00a0 | 33,369\u00a0 | |||||||||
| Unamortized debt issuance costs and debt discount | (17,624) | (12,311) | |||||||||
| Total debt | 375,783\u00a0 | 385,112\u00a0 | |||||||||
| Less current portion of long-term debt: | (22,457) | (68,523) | |||||||||
| Long-term debt | $ | 353,326\u00a0 | $ | 316,589\u00a0 |
| (in thousands) | Remainder fiscal 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | Total | ||||||||||||||||||||||||||||||||||
Term Loan | $ | 2,031\u00a0 | $ | 8,125\u00a0 | $ | 14,219\u00a0 | $ | 16,250\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 325,000\u00a0 | |||||||||||||||||||||||||||
| Class A Notes | 2,707\u00a0 | 10,593\u00a0 | 8,650\u00a0 | 19,094\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 41,044\u00a0 | ||||||||||||||||||||||||||||||||||
| Class B Notes | 1,805\u00a0 | 7,062\u00a0 | 5,767\u00a0 | 12,729\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 27,363\u00a0 | ||||||||||||||||||||||||||||||||||
| Total obligations | $ | 6,543\u00a0 | $ | 25,780\u00a0 | $ | 28,636\u00a0 | $ | 48,073\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 393,407\u00a0 |
| (in thousands) | March 31, 2026 | June 30, 2025 | |||||||||
Term Loan | $ | 325,000\u00a0 | $ | \u2014\u00a0 | |||||||
Previous Term Loans | \u2014\u00a0 | 314,000\u00a0 | |||||||||
Class A Notes | 41,044\u00a0 | 50,054\u00a0 | |||||||||
Class B Notes | 27,363\u00a0 | 33,369\u00a0 | |||||||||
| Unamortized debt issuance costs and debt discount | (17,624) | (12,311) | |||||||||
| Total debt | 375,783\u00a0 | 385,112\u00a0 | |||||||||
| Less current portion of long-term debt: | (22,457) | (68,523) | |||||||||
| Long-term debt | $ | 353,326\u00a0 | $ | 316,589\u00a0 |
| (in thousands) | Remainder fiscal 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | Total | ||||||||||||||||||||||||||||||||||
Term Loan | $ | 2,031\u00a0 | $ | 8,125\u00a0 | $ | 14,219\u00a0 | $ | 16,250\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 325,000\u00a0 | |||||||||||||||||||||||||||
| Class A Notes | 2,707\u00a0 | 10,593\u00a0 | 8,650\u00a0 | 19,094\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 41,044\u00a0 | ||||||||||||||||||||||||||||||||||
| Class B Notes | 1,805\u00a0 | 7,062\u00a0 | 5,767\u00a0 | 12,729\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 27,363\u00a0 | ||||||||||||||||||||||||||||||||||
| Total obligations | $ | 6,543\u00a0 | $ | 25,780\u00a0 | $ | 28,636\u00a0 | $ | 48,073\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 393,407\u00a0 |
As of March\u00a031, 2026 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 16,836\u00a0 | $ | 16,836\u00a0 |
As of June 30, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 322\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 322\u00a0 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 78,657\u00a0 | $ | 78,657\u00a0 |
| March 31, 2026 | |||||
Tranche 1 | |||||
Stock price(1) | $ | 0.63\u00a0 | |||
| Exercise price | $ | 3.00\u00a0 | |||
Expected volatility | 104.73\u00a0 | % | |||
| Risk-free interest rate | 3.77\u00a0 | % | |||
Expected dividend-yield | \u2014\u00a0 | % | |||
Expected life | 3.54 years | ||||
Fair value per warrant | $ | 0.27\u00a0 |
| March 31, 2026 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 0.63\u00a0 | $ | 0.63\u00a0 | $ | 0.63\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
| Expected volatility | 101.71\u00a0 | % | 101.71\u00a0 | % | 101.71\u00a0 | % | |||||
| Risk-free interest rate | 4.18\u00a0 | % | 4.18\u00a0 | % | 4.18\u00a0 | % | |||||
| Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
| Expected life | 8.87 years | 8.87 years | 8.87 years | ||||||||
| Fair value per warrant | $ | 0.63\u00a0 | $ | 0.47\u00a0 | $ | 0.45\u00a0 |
| (in thousands) | Warrant Liability | ||||
Balance as of June\u00a030, 2025 | $ | 78,657\u00a0 | |||
| Change in fair value | (57,580) | ||||
| Cancellation of Eleventh Amendment Tranche 2-4 Warrants | (4,241) | ||||
Balance as of March\u00a031, 2026 | $ | 16,836\u00a0 |
As of March\u00a031, 2026 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 16,836\u00a0 | $ | 16,836\u00a0 |
As of June 30, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 322\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 322\u00a0 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 78,657\u00a0 | $ | 78,657\u00a0 |
| March 31, 2026 | |||||
Tranche 1 | |||||
Stock price(1) | $ | 0.63\u00a0 | |||
| Exercise price | $ | 3.00\u00a0 | |||
Expected volatility | 104.73\u00a0 | % | |||
| Risk-free interest rate | 3.77\u00a0 | % | |||
Expected dividend-yield | \u2014\u00a0 | % | |||
Expected life | 3.54 years | ||||
Fair value per warrant | $ | 0.27\u00a0 |
| March 31, 2026 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 0.63\u00a0 | $ | 0.63\u00a0 | $ | 0.63\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
| Expected volatility | 101.71\u00a0 | % | 101.71\u00a0 | % | 101.71\u00a0 | % | |||||
| Risk-free interest rate | 4.18\u00a0 | % | 4.18\u00a0 | % | 4.18\u00a0 | % | |||||
| Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
| Expected life | 8.87 years | 8.87 years | 8.87 years | ||||||||
| Fair value per warrant | $ | 0.63\u00a0 | $ | 0.47\u00a0 | $ | 0.45\u00a0 |
| (in thousands) | Warrant Liability | ||||
Balance as of June\u00a030, 2025 | $ | 78,657\u00a0 | |||
| Change in fair value | (57,580) | ||||
| Cancellation of Eleventh Amendment Tranche 2-4 Warrants | (4,241) | ||||
Balance as of March\u00a031, 2026 | $ | 16,836\u00a0 |
| ESPP | 159\u00a0 | |||||||
| Stock awards outstanding under 2020 Plan | 20,889,048\u00a0 | |||||||
| Stock awards available for grant under 2020 Plan | 1,711,678\u00a0 | |||||||
| Options outstanding under 2003 Plan | 424,295\u00a0 | |||||||
| Total | 23,025,180\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Share-based compensation related to: | ||||||||||||||||||||||||||
| Equity classified stock options | $ | 46\u00a0 | $ | 376\u00a0 | $ | 283\u00a0 | $ | 1,226\u00a0 | ||||||||||||||||||
Equity classified RSUs | 2,415\u00a0 | 2,611\u00a0 | 7,359\u00a0 | 7,546\u00a0 | ||||||||||||||||||||||
Equity classified PVUs | 1,217\u00a0 | 1,973\u00a0 | 3,838\u00a0 | 4,733\u00a0 | ||||||||||||||||||||||
| Total | $ | 3,678\u00a0 | $ | 4,960\u00a0 | $ | 11,480\u00a0 | $ | 13,505\u00a0 |
| Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (in Years) | Aggregate Intrinsic Value (in Thousands) | |||||||||||
Outstanding\u2014June\u00a030, 2025 | 3,338,025\u00a0 | $ | 12.30\u00a0 | |||||||||||
| Options forfeited/expired/cancelled | (135,373) | 15.45\u00a0 | ||||||||||||
Outstanding\u2014March\u00a031, 2026 | 3,202,652\u00a0 | $ | 12.17\u00a0 | 4.70 | $ | \u2014\u00a0 | ||||||||
Vested and exercisable\u2014March\u00a031, 2026 | 3,201,121\u00a0 | $ | 12.17\u00a0 | 4.69 | $ | \u2014\u00a0 |
| Number of Restricted Stock Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 8,389,188\u00a0 | $ | 2.30\u00a0 | ||||||||
| Granted | 5,858,922\u00a0 | 1.72\u00a0 | |||||||||
| Vested | (4,245,248) | 2.29\u00a0 | |||||||||
| Forfeited | (331,089) | 2.16\u00a0 | |||||||||
Unvested as of March\u00a031, 2026 | 9,671,773\u00a0 | $ | 1.96\u00a0 |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 636,666\u00a0 | $ | 1.67\u00a0 | $ | 2.50\u00a0 | August 1, 2025 - August 1, 2030 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 636,668\u00a0 | $ | 1.59\u00a0 | $ | 4.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.14 years - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 636,666\u00a0 | $ | 1.49\u00a0 | $ | 6.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.62 years - 3 years |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 772,027\u00a0 | $ | 3.98\u00a0 | $ | 3.13\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 772,020\u00a0 | $ | 3.75\u00a0 | $ | 6.00\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 772,027\u00a0 | $ | 3.49\u00a0 | $ | 9.00\u00a0 | August 1, 2024 - August 1, 2029 | 1.31 years - 3 years |
Shares Granted August 1, 2025 | Shares Granted August 1, 2024 | |||||||||||||
| Share price as of grant date | $1.74 | $4.01 | ||||||||||||
| Volatility | 104.2% | 88.8% | ||||||||||||
| Risk-free interest rate | 3.7% | 3.8% | ||||||||||||
| Cost of Equity | 15.8% | 12.6% | ||||||||||||
| Dividend yield | \u2014% | \u2014% |
| Number of Price-Vested Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 7,481,813\u00a0 | $ | 2.11\u00a0 | ||||||||
| Granted | 1,910,000\u00a0 | $ | 1.58\u00a0 | ||||||||
| Vested | (755,544) | $ | 2.17\u00a0 | ||||||||
| Forfeited | (197,351) | $ | 2.09\u00a0 | ||||||||
Unvested as of March\u00a031, 2026 | 8,438,918\u00a0 | $ | 1.98\u00a0 |
| ESPP | 159\u00a0 | |||||||
| Stock awards outstanding under 2020 Plan | 20,889,048\u00a0 | |||||||
| Stock awards available for grant under 2020 Plan | 1,711,678\u00a0 | |||||||
| Options outstanding under 2003 Plan | 424,295\u00a0 | |||||||
| Total | 23,025,180\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Share-based compensation related to: | ||||||||||||||||||||||||||
| Equity classified stock options | $ | 46\u00a0 | $ | 376\u00a0 | $ | 283\u00a0 | $ | 1,226\u00a0 | ||||||||||||||||||
Equity classified RSUs | 2,415\u00a0 | 2,611\u00a0 | 7,359\u00a0 | 7,546\u00a0 | ||||||||||||||||||||||
Equity classified PVUs | 1,217\u00a0 | 1,973\u00a0 | 3,838\u00a0 | 4,733\u00a0 | ||||||||||||||||||||||
| Total | $ | 3,678\u00a0 | $ | 4,960\u00a0 | $ | 11,480\u00a0 | $ | 13,505\u00a0 |
| Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (in Years) | Aggregate Intrinsic Value (in Thousands) | |||||||||||
Outstanding\u2014June\u00a030, 2025 | 3,338,025\u00a0 | $ | 12.30\u00a0 | |||||||||||
| Options forfeited/expired/cancelled | (135,373) | 15.45\u00a0 | ||||||||||||
Outstanding\u2014March\u00a031, 2026 | 3,202,652\u00a0 | $ | 12.17\u00a0 | 4.70 | $ | \u2014\u00a0 | ||||||||
Vested and exercisable\u2014March\u00a031, 2026 | 3,201,121\u00a0 | $ | 12.17\u00a0 | 4.69 | $ | \u2014\u00a0 |
| Number of Restricted Stock Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 8,389,188\u00a0 | $ | 2.30\u00a0 | ||||||||
| Granted | 5,858,922\u00a0 | 1.72\u00a0 | |||||||||
| Vested | (4,245,248) | 2.29\u00a0 | |||||||||
| Forfeited | (331,089) | 2.16\u00a0 | |||||||||
Unvested as of March\u00a031, 2026 | 9,671,773\u00a0 | $ | 1.96\u00a0 |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 636,666\u00a0 | $ | 1.67\u00a0 | $ | 2.50\u00a0 | August 1, 2025 - August 1, 2030 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 636,668\u00a0 | $ | 1.59\u00a0 | $ | 4.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.14 years - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 636,666\u00a0 | $ | 1.49\u00a0 | $ | 6.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.62 years - 3 years |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 772,027\u00a0 | $ | 3.98\u00a0 | $ | 3.13\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 772,020\u00a0 | $ | 3.75\u00a0 | $ | 6.00\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 772,027\u00a0 | $ | 3.49\u00a0 | $ | 9.00\u00a0 | August 1, 2024 - August 1, 2029 | 1.31 years - 3 years |
Shares Granted August 1, 2025 | Shares Granted August 1, 2024 | |||||||||||||
| Share price as of grant date | $1.74 | $4.01 | ||||||||||||
| Volatility | 104.2% | 88.8% | ||||||||||||
| Risk-free interest rate | 3.7% | 3.8% | ||||||||||||
| Cost of Equity | 15.8% | 12.6% | ||||||||||||
| Dividend yield | \u2014% | \u2014% |
| Number of Price-Vested Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 7,481,813\u00a0 | $ | 2.11\u00a0 | ||||||||
| Granted | 1,910,000\u00a0 | $ | 1.58\u00a0 | ||||||||
| Vested | (755,544) | $ | 2.17\u00a0 | ||||||||
| Forfeited | (197,351) | $ | 2.09\u00a0 | ||||||||
Unvested as of March\u00a031, 2026 | 8,438,918\u00a0 | $ | 1.98\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
(in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Senior: | |||||||||||||||||||||||
| Medicare advantage commissions | $ | 174,132\u00a0 | $ | 145,453\u00a0 | $ | 447,040\u00a0 | $ | 446,640\u00a0 | |||||||||||||||
Other Senior commissions | 3,282\u00a0 | 3,345\u00a0 | 12,220\u00a0 | 8,111\u00a0 | |||||||||||||||||||
| Other services | 5,476\u00a0 | 20,644\u00a0 | 44,166\u00a0 | 63,179\u00a0 | |||||||||||||||||||
| Total Senior revenue | 182,890\u00a0 | 169,442\u00a0 | 503,426\u00a0 | 517,930\u00a0 | |||||||||||||||||||
| Healthcare Services: | |||||||||||||||||||||||
| Pharmacy | 195,270\u00a0 | 185,271\u00a0 | 641,023\u00a0 | 518,154\u00a0 | |||||||||||||||||||
| Other services | 4,116\u00a0 | 4,298\u00a0 | 10,368\u00a0 | 10,523\u00a0 | |||||||||||||||||||
| Total Healthcare Services revenue | 199,386\u00a0 | 189,569\u00a0 | 651,391\u00a0 | 528,677\u00a0 | |||||||||||||||||||
| Life: | |||||||||||||||||||||||
| Term commissions | 20,605\u00a0 | 20,139\u00a0 | 58,372\u00a0 | 55,169\u00a0 | |||||||||||||||||||
| Final expense commissions | 21,860\u00a0 | 20,188\u00a0 | 64,194\u00a0 | 54,795\u00a0 | |||||||||||||||||||
| Other services | 5,431\u00a0 | 5,515\u00a0 | 15,600\u00a0 | 15,029\u00a0 | |||||||||||||||||||
| Total Life revenue | 47,896\u00a0 | 45,842\u00a0 | 138,166\u00a0 | 124,993\u00a0 | |||||||||||||||||||
| All other: | |||||||||||||||||||||||
| Commissions | 2,818\u00a0 | 4,900\u00a0 | 9,085\u00a0 | 14,667\u00a0 | |||||||||||||||||||
| Other services | 266\u00a0 | 377\u00a0 | 1,537\u00a0 | 717\u00a0 | |||||||||||||||||||
Total All other revenue | 3,084\u00a0 | 5,277\u00a0 | 10,622\u00a0 | 15,384\u00a0 | |||||||||||||||||||
| Eliminations: | |||||||||||||||||||||||
| Commissions | (994) | (867) | (2,807) | (2,531) | |||||||||||||||||||
| Other services | (1,329) | (1,103) | (3,952) | (2,961) | |||||||||||||||||||
| Total Elimination revenue | (2,323) | (1,970) | (6,759) | (5,492) | |||||||||||||||||||
| Total Commissions and other services revenue | 235,663\u00a0 | 222,889\u00a0 | 655,823\u00a0 | 663,338\u00a0 | |||||||||||||||||||
| Total Pharmacy revenue | 195,270\u00a0 | 185,271\u00a0 | 641,023\u00a0 | 518,154\u00a0 | |||||||||||||||||||
| Total Revenue | $ | 430,933\u00a0 | $ | 408,160\u00a0 | $ | 1,296,846\u00a0 | $ | 1,181,492\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2025 | $ | 950,828\u00a0 | ||||||
| Commission revenue from revenue recognized | 244,027\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | 14,277\u00a0 | |||||||
| Amounts recognized as accounts receivable, net | (249,603) | |||||||
Balance as of March\u00a031, 2026 | $ | 959,529\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2025 | $ | 698\u00a0 | ||||||
| Commission and other services revenue recognized | (14,057) | |||||||
| Amounts recognized as contract liabilities | 13,640\u00a0 | |||||||
Balance as of March\u00a031, 2026 | $ | 281\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
(in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Senior: | |||||||||||||||||||||||
| Medicare advantage commissions | $ | 174,132\u00a0 | $ | 145,453\u00a0 | $ | 447,040\u00a0 | $ | 446,640\u00a0 | |||||||||||||||
Other Senior commissions | 3,282\u00a0 | 3,345\u00a0 | 12,220\u00a0 | 8,111\u00a0 | |||||||||||||||||||
| Other services | 5,476\u00a0 | 20,644\u00a0 | 44,166\u00a0 | 63,179\u00a0 | |||||||||||||||||||
| Total Senior revenue | 182,890\u00a0 | 169,442\u00a0 | 503,426\u00a0 | 517,930\u00a0 | |||||||||||||||||||
| Healthcare Services: | |||||||||||||||||||||||
| Pharmacy | 195,270\u00a0 | 185,271\u00a0 | 641,023\u00a0 | 518,154\u00a0 | |||||||||||||||||||
| Other services | 4,116\u00a0 | 4,298\u00a0 | 10,368\u00a0 | 10,523\u00a0 | |||||||||||||||||||
| Total Healthcare Services revenue | 199,386\u00a0 | 189,569\u00a0 | 651,391\u00a0 | 528,677\u00a0 | |||||||||||||||||||
| Life: | |||||||||||||||||||||||
| Term commissions | 20,605\u00a0 | 20,139\u00a0 | 58,372\u00a0 | 55,169\u00a0 | |||||||||||||||||||
| Final expense commissions | 21,860\u00a0 | 20,188\u00a0 | 64,194\u00a0 | 54,795\u00a0 | |||||||||||||||||||
| Other services | 5,431\u00a0 | 5,515\u00a0 | 15,600\u00a0 | 15,029\u00a0 | |||||||||||||||||||
| Total Life revenue | 47,896\u00a0 | 45,842\u00a0 | 138,166\u00a0 | 124,993\u00a0 | |||||||||||||||||||
| All other: | |||||||||||||||||||||||
| Commissions | 2,818\u00a0 | 4,900\u00a0 | 9,085\u00a0 | 14,667\u00a0 | |||||||||||||||||||
| Other services | 266\u00a0 | 377\u00a0 | 1,537\u00a0 | 717\u00a0 | |||||||||||||||||||
Total All other revenue | 3,084\u00a0 | 5,277\u00a0 | 10,622\u00a0 | 15,384\u00a0 | |||||||||||||||||||
| Eliminations: | |||||||||||||||||||||||
| Commissions | (994) | (867) | (2,807) | (2,531) | |||||||||||||||||||
| Other services | (1,329) | (1,103) | (3,952) | (2,961) | |||||||||||||||||||
| Total Elimination revenue | (2,323) | (1,970) | (6,759) | (5,492) | |||||||||||||||||||
| Total Commissions and other services revenue | 235,663\u00a0 | 222,889\u00a0 | 655,823\u00a0 | 663,338\u00a0 | |||||||||||||||||||
| Total Pharmacy revenue | 195,270\u00a0 | 185,271\u00a0 | 641,023\u00a0 | 518,154\u00a0 | |||||||||||||||||||
| Total Revenue | $ | 430,933\u00a0 | $ | 408,160\u00a0 | $ | 1,296,846\u00a0 | $ | 1,181,492\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2025 | $ | 950,828\u00a0 | ||||||
| Commission revenue from revenue recognized | 244,027\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | 14,277\u00a0 | |||||||
| Amounts recognized as accounts receivable, net | (249,603) | |||||||
Balance as of March\u00a031, 2026 | $ | 959,529\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2025 | $ | 698\u00a0 | ||||||
| Commission and other services revenue recognized | (14,057) | |||||||
| Amounts recognized as contract liabilities | 13,640\u00a0 | |||||||
Balance as of March\u00a031, 2026 | $ | 281\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||
(in thousands, except per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Numerator: | ||||||||||||||||||||
| Net income attributable to common shareholders, basic | $ | 21,422\u00a0 | $ | 20,235\u00a0 | $ | 24,649\u00a0 | $ | 28,925\u00a0 | ||||||||||||
| \u2014\u00a0 | (13,803) | (3,539) | (6,160) | |||||||||||||||||
| Net income attributable to common shareholders, diluted | 21,422\u00a0 | 6,432\u00a0 | 21,110\u00a0 | 22,765\u00a0 | ||||||||||||||||
| Denominator: | ||||||||||||||||||||
| Weighted-average common stock outstanding, basic | 189,455\u00a0 | 178,156\u00a0 | 187,614\u00a0 | 173,462\u00a0 | ||||||||||||||||
| Stock options outstanding to purchase shares of common stock including unvested RSUs and from the ESPP | 691\u00a0 | 5,738\u00a0 | 1,580\u00a0 | 4,518\u00a0 | ||||||||||||||||
| Dilutive effect of warrants to purchase common stock | 335\u00a0 | 2,745\u00a0 | 1,453\u00a0 | 915\u00a0 | ||||||||||||||||
Weighted-average common stock outstanding, diluted | 190,481\u00a0 | 186,639\u00a0 | 190,647\u00a0 | 178,895\u00a0 | ||||||||||||||||
| Net income per share\u2014basic: | $ | 0.11\u00a0 | $ | 0.11\u00a0 | $ | 0.13\u00a0 | $ | 0.17\u00a0 | ||||||||||||
| Net income per share\u2014diluted: | $ | 0.11\u00a0 | $ | 0.03\u00a0 | $ | 0.11\u00a0 | $ | 0.13\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Stock options outstanding to purchase shares of common stock, unvested RSUs and shares from the ESPP | 11,095\u00a0 | 2,161\u00a0 | 6,932\u00a0 | 3,496\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Shares subject to outstanding PVUs | 8,439\u00a0 | 7,482\u00a0 | 8,497\u00a0 | 7,422\u00a0 | |||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Warrants to purchase shares of common stock | 18,744\u00a0 | 7,241\u00a0 | 21,528\u00a0 | 4,270\u00a0 | |||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||
(in thousands, except per share amounts) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||
| Numerator: | ||||||||||||||||||||
| Net income attributable to common shareholders, basic | $ | 21,422\u00a0 | $ | 20,235\u00a0 | $ | 24,649\u00a0 | $ | 28,925\u00a0 | ||||||||||||
| \u2014\u00a0 | (13,803) | (3,539) | (6,160) | |||||||||||||||||
| Net income attributable to common shareholders, diluted | 21,422\u00a0 | 6,432\u00a0 | 21,110\u00a0 | 22,765\u00a0 | ||||||||||||||||
| Denominator: | ||||||||||||||||||||
| Weighted-average common stock outstanding, basic | 189,455\u00a0 | 178,156\u00a0 | 187,614\u00a0 | 173,462\u00a0 | ||||||||||||||||
| Stock options outstanding to purchase shares of common stock including unvested RSUs and from the ESPP | 691\u00a0 | 5,738\u00a0 | 1,580\u00a0 | 4,518\u00a0 | ||||||||||||||||
| Dilutive effect of warrants to purchase common stock | 335\u00a0 | 2,745\u00a0 | 1,453\u00a0 | 915\u00a0 | ||||||||||||||||
Weighted-average common stock outstanding, diluted | 190,481\u00a0 | 186,639\u00a0 | 190,647\u00a0 | 178,895\u00a0 | ||||||||||||||||
| Net income per share\u2014basic: | $ | 0.11\u00a0 | $ | 0.11\u00a0 | $ | 0.13\u00a0 | $ | 0.17\u00a0 | ||||||||||||
| Net income per share\u2014diluted: | $ | 0.11\u00a0 | $ | 0.03\u00a0 | $ | 0.11\u00a0 | $ | 0.13\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Stock options outstanding to purchase shares of common stock, unvested RSUs and shares from the ESPP | 11,095\u00a0 | 2,161\u00a0 | 6,932\u00a0 | 3,496\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
Shares subject to outstanding PVUs | 8,439\u00a0 | 7,482\u00a0 | 8,497\u00a0 | 7,422\u00a0 | |||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Warrants to purchase shares of common stock | 18,744\u00a0 | 7,241\u00a0 | 21,528\u00a0 | 4,270\u00a0 | |||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 180,879\u00a0 | $ | 199,096\u00a0 | $ | 47,874\u00a0 | $ | 427,849\u00a0 | |||||||||||||||
| Intersegment revenue | 2,011\u00a0 | 290\u00a0 | 22\u00a0 | 2,323\u00a0 | |||||||||||||||||||
| Total revenue from reportable segments | $ | 182,890\u00a0 | $ | 199,386\u00a0 | $ | 47,896\u00a0 | $ | 430,172\u00a0 | |||||||||||||||
All other revenue (1) | 3,084\u00a0 | ||||||||||||||||||||||
| Eliminations of intersegment revenues | (2,323) | ||||||||||||||||||||||
| Total consolidated revenue | $ | 430,933\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 182,890\u00a0 | $ | 199,386\u00a0 | $ | 47,896\u00a0 | $ | 430,172\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (54,596) | (6,976) | (18,465) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (169,814) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (69,060) | (1,686) | (23,131) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (318) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (592) | (15,314) | (216) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 58,642\u00a0 | $ | 5,278\u00a0 | $ | 6,084\u00a0 | $ | 70,004\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 1,376\u00a0 | ||||||||||||||||||||||
Corporate (5) | (26,790) | ||||||||||||||||||||||
| Share-based compensation expense | (3,678) | ||||||||||||||||||||||
Transaction costs (6) | (631) | ||||||||||||||||||||||
| Depreciation and amortization | (4,385) | ||||||||||||||||||||||
Loss on extinguishment of debt | (8,659) | ||||||||||||||||||||||
| Change in fair value of warrants | 27,489\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (10,602) | ||||||||||||||||||||||
Income before income tax expense | $ | 44,124\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 167,565\u00a0 | $ | 189,496\u00a0 | $ | 45,822\u00a0 | $ | 402,883\u00a0 | |||||||||||||||
| Intersegment revenue | 1,877\u00a0 | 73\u00a0 | 20\u00a0 | 1,970\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 169,442\u00a0 | $ | 189,569\u00a0 | $ | 45,842\u00a0 | $ | 404,853\u00a0 | |||||||||||||||
All other revenue (1) | 5,277\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (1,970) | ||||||||||||||||||||||
Total consolidated revenue | $ | 408,160\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 169,442\u00a0 | $ | 189,569\u00a0 | $ | 45,842\u00a0 | $ | 404,853\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (53,374) | (5,816) | (17,415) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (161,026) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (69,808) | (1,939) | (21,789) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (491) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (559) | (13,852) | (274) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 45,701\u00a0 | $ | 6,445\u00a0 | $ | 6,364\u00a0 | $ | 58,510\u00a0 | |||||||||||||||
| Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 3,549\u00a0 | ||||||||||||||||||||||
Corporate (5) | (24,336) | ||||||||||||||||||||||
| Share-based compensation expense | (4,960) | ||||||||||||||||||||||
Transaction costs (6) | (5,813) | ||||||||||||||||||||||
| Depreciation and amortization | (4,925) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (3) | ||||||||||||||||||||||
| Change in fair value of warrants | 32,986\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (20,407) | ||||||||||||||||||||||
Income before income tax expense | $ | 34,601\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 497,378\u00a0 | $ | 650,745\u00a0 | $ | 138,101\u00a0 | $ | 1,286,224\u00a0 | |||||||||||||||
| Intersegment revenue | 6,048\u00a0 | 646\u00a0 | 65\u00a0 | 6,759\u00a0 | |||||||||||||||||||
| Total revenue from reportable segments | $ | 503,426\u00a0 | $ | 651,391\u00a0 | $ | 138,166\u00a0 | $ | 1,292,983\u00a0 | |||||||||||||||
All other revenue (1) | 10,622\u00a0 | ||||||||||||||||||||||
| Eliminations of intersegment revenues | (6,759) | ||||||||||||||||||||||
| Total consolidated revenue | $ | 1,296,846\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 503,426\u00a0 | $ | 651,391\u00a0 | $ | 138,166\u00a0 | $ | 1,292,983\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (170,884) | (21,635) | (53,848) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (564,995) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (190,746) | (6,309) | (66,267) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (1,068) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (1,739) | (44,048) | (815) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 140,057\u00a0 | $ | 13,336\u00a0 | $ | 17,236\u00a0 | $ | 170,629\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 5,366\u00a0 | ||||||||||||||||||||||
Corporate (5) | (78,752) | ||||||||||||||||||||||
| Share-based compensation expense | (11,480) | ||||||||||||||||||||||
Transaction costs (6) | (1,478) | ||||||||||||||||||||||
| Depreciation and amortization | (13,007) | ||||||||||||||||||||||
Impairment of equity-method investment (7) | (1,000) | ||||||||||||||||||||||
Loss on extinguishment of debt | (8,659) | ||||||||||||||||||||||
| Change in fair value of warrants | 61,821\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (34,023) | ||||||||||||||||||||||
Income before income tax expense | $ | 89,417\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 512,735\u00a0 | $ | 528,443\u00a0 | $ | 124,930\u00a0 | $ | 1,166,108\u00a0 | |||||||||||||||
| Intersegment revenue | 5,195\u00a0 | 234\u00a0 | 63\u00a0 | 5,492\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 517,930\u00a0 | $ | 528,677\u00a0 | $ | 124,993\u00a0 | $ | 1,171,600\u00a0 | |||||||||||||||
All other revenue (1) | 15,384\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (5,492) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,181,492\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 517,930\u00a0 | $ | 528,677\u00a0 | $ | 124,993\u00a0 | $ | 1,171,600\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (169,543) | (19,627) | (47,028) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (444,401) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (192,583) | (6,088) | (57,456) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (1,691) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (1,855) | (43,336) | (762) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 153,949\u00a0 | $ | 13,534\u00a0 | $ | 19,747\u00a0 | $ | 187,230\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 9,645\u00a0 | ||||||||||||||||||||||
Corporate (5) | (73,316) | ||||||||||||||||||||||
| Share-based compensation expense | (13,505) | ||||||||||||||||||||||
Transaction costs (6) | (13,358) | ||||||||||||||||||||||
| Depreciation and amortization | (15,584) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (160) | ||||||||||||||||||||||
| Change in fair value of warrants | 25,344\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (67,160) | ||||||||||||||||||||||
Income before income tax expense | $ | 39,136\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 180,879\u00a0 | $ | 199,096\u00a0 | $ | 47,874\u00a0 | $ | 427,849\u00a0 | |||||||||||||||
| Intersegment revenue | 2,011\u00a0 | 290\u00a0 | 22\u00a0 | 2,323\u00a0 | |||||||||||||||||||
| Total revenue from reportable segments | $ | 182,890\u00a0 | $ | 199,386\u00a0 | $ | 47,896\u00a0 | $ | 430,172\u00a0 | |||||||||||||||
All other revenue (1) | 3,084\u00a0 | ||||||||||||||||||||||
| Eliminations of intersegment revenues | (2,323) | ||||||||||||||||||||||
| Total consolidated revenue | $ | 430,933\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 182,890\u00a0 | $ | 199,386\u00a0 | $ | 47,896\u00a0 | $ | 430,172\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (54,596) | (6,976) | (18,465) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (169,814) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (69,060) | (1,686) | (23,131) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (318) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (592) | (15,314) | (216) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 58,642\u00a0 | $ | 5,278\u00a0 | $ | 6,084\u00a0 | $ | 70,004\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 1,376\u00a0 | ||||||||||||||||||||||
Corporate (5) | (26,790) | ||||||||||||||||||||||
| Share-based compensation expense | (3,678) | ||||||||||||||||||||||
Transaction costs (6) | (631) | ||||||||||||||||||||||
| Depreciation and amortization | (4,385) | ||||||||||||||||||||||
Loss on extinguishment of debt | (8,659) | ||||||||||||||||||||||
| Change in fair value of warrants | 27,489\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (10,602) | ||||||||||||||||||||||
Income before income tax expense | $ | 44,124\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 167,565\u00a0 | $ | 189,496\u00a0 | $ | 45,822\u00a0 | $ | 402,883\u00a0 | |||||||||||||||
| Intersegment revenue | 1,877\u00a0 | 73\u00a0 | 20\u00a0 | 1,970\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 169,442\u00a0 | $ | 189,569\u00a0 | $ | 45,842\u00a0 | $ | 404,853\u00a0 | |||||||||||||||
All other revenue (1) | 5,277\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (1,970) | ||||||||||||||||||||||
Total consolidated revenue | $ | 408,160\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 169,442\u00a0 | $ | 189,569\u00a0 | $ | 45,842\u00a0 | $ | 404,853\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (53,374) | (5,816) | (17,415) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (161,026) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (69,808) | (1,939) | (21,789) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (491) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (559) | (13,852) | (274) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 45,701\u00a0 | $ | 6,445\u00a0 | $ | 6,364\u00a0 | $ | 58,510\u00a0 | |||||||||||||||
| Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 3,549\u00a0 | ||||||||||||||||||||||
Corporate (5) | (24,336) | ||||||||||||||||||||||
| Share-based compensation expense | (4,960) | ||||||||||||||||||||||
Transaction costs (6) | (5,813) | ||||||||||||||||||||||
| Depreciation and amortization | (4,925) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (3) | ||||||||||||||||||||||
| Change in fair value of warrants | 32,986\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (20,407) | ||||||||||||||||||||||
Income before income tax expense | $ | 34,601\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 497,378\u00a0 | $ | 650,745\u00a0 | $ | 138,101\u00a0 | $ | 1,286,224\u00a0 | |||||||||||||||
| Intersegment revenue | 6,048\u00a0 | 646\u00a0 | 65\u00a0 | 6,759\u00a0 | |||||||||||||||||||
| Total revenue from reportable segments | $ | 503,426\u00a0 | $ | 651,391\u00a0 | $ | 138,166\u00a0 | $ | 1,292,983\u00a0 | |||||||||||||||
All other revenue (1) | 10,622\u00a0 | ||||||||||||||||||||||
| Eliminations of intersegment revenues | (6,759) | ||||||||||||||||||||||
| Total consolidated revenue | $ | 1,296,846\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 503,426\u00a0 | $ | 651,391\u00a0 | $ | 138,166\u00a0 | $ | 1,292,983\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (170,884) | (21,635) | (53,848) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (564,995) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (190,746) | (6,309) | (66,267) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (1,068) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (1,739) | (44,048) | (815) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 140,057\u00a0 | $ | 13,336\u00a0 | $ | 17,236\u00a0 | $ | 170,629\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 5,366\u00a0 | ||||||||||||||||||||||
Corporate (5) | (78,752) | ||||||||||||||||||||||
| Share-based compensation expense | (11,480) | ||||||||||||||||||||||
Transaction costs (6) | (1,478) | ||||||||||||||||||||||
| Depreciation and amortization | (13,007) | ||||||||||||||||||||||
Impairment of equity-method investment (7) | (1,000) | ||||||||||||||||||||||
Loss on extinguishment of debt | (8,659) | ||||||||||||||||||||||
| Change in fair value of warrants | 61,821\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (34,023) | ||||||||||||||||||||||
Income before income tax expense | $ | 89,417\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 512,735\u00a0 | $ | 528,443\u00a0 | $ | 124,930\u00a0 | $ | 1,166,108\u00a0 | |||||||||||||||
| Intersegment revenue | 5,195\u00a0 | 234\u00a0 | 63\u00a0 | 5,492\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 517,930\u00a0 | $ | 528,677\u00a0 | $ | 124,993\u00a0 | $ | 1,171,600\u00a0 | |||||||||||||||
All other revenue (1) | 15,384\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (5,492) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,181,492\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 517,930\u00a0 | $ | 528,677\u00a0 | $ | 124,993\u00a0 | $ | 1,171,600\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (169,543) | (19,627) | (47,028) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (444,401) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (192,583) | (6,088) | (57,456) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (1,691) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (1,855) | (43,336) | (762) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 153,949\u00a0 | $ | 13,534\u00a0 | $ | 19,747\u00a0 | $ | 187,230\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 9,645\u00a0 | ||||||||||||||||||||||
Corporate (5) | (73,316) | ||||||||||||||||||||||
| Share-based compensation expense | (13,505) | ||||||||||||||||||||||
Transaction costs (6) | (13,358) | ||||||||||||||||||||||
| Depreciation and amortization | (15,584) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (160) | ||||||||||||||||||||||
| Change in fair value of warrants | 25,344\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (67,160) | ||||||||||||||||||||||
Income before income tax expense | $ | 39,136\u00a0 |